Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 July 2014Website:
http://www.matinasbiopharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 20 min agoDividend
Analysts recommendations
Institutional Ownership
MTNB Latest News
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
What type of business is Matinas BioPharma Holdings?
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
What sector is Matinas BioPharma Holdings in?
Matinas BioPharma Holdings is in the Healthcare sector
What industry is Matinas BioPharma Holdings in?
Matinas BioPharma Holdings is in the Biotechnology industry
What country is Matinas BioPharma Holdings from?
Matinas BioPharma Holdings is headquartered in United States
When did Matinas BioPharma Holdings go public?
Matinas BioPharma Holdings initial public offering (IPO) was on 21 July 2014
What is Matinas BioPharma Holdings website?
https://www.matinasbiopharma.com
Is Matinas BioPharma Holdings in the S&P 500?
No, Matinas BioPharma Holdings is not included in the S&P 500 index
Is Matinas BioPharma Holdings in the NASDAQ 100?
No, Matinas BioPharma Holdings is not included in the NASDAQ 100 index
Is Matinas BioPharma Holdings in the Dow Jones?
No, Matinas BioPharma Holdings is not included in the Dow Jones index
When does Matinas BioPharma Holdings report earnings?
The next expected earnings date for Matinas BioPharma Holdings is 09 August 2024